TY - JOUR AU - D’Costa, Ninadh Malrina AU - Chavez-Munoz, Claudia AU - So, Alan I. PY - 2017 TI - Role of fibroblast growth factor receptor in sunitinib-resistant renal cell carcinoma JF - Biotarget; Vol 1 (May 2017): Biotarget Y2 - 2017 KW - N2 - In renal cell carcinoma (RCC), surgical therapy remains to be the only curative approach for patients with localised kidney tumor, with recurrence rates as high as 40% in high risk patients. As well, even though there are now many approved therapies for metastatic RCC (mRCC), resistance eventually develops and is fatal for metastatic patients. Tyrosine kinase inhibitors (TKIs) that target the VEGF pathway are considered first-line therapy for clear cell RCC, the most common type of RCC. UR - https://biotarget.amegroups.org/article/view/3655